Sandra Close
Directeur des opérations chez Foresight Diagnostics, Inc.
Profil
Sandra Close is currently the Director at Dante Labs, Inc., Director at Dante Labs International LLC, and Chief Operating Officer at Foresight Diagnostics, Inc. Her former positions include Chief Diagnostics Strategy Officer at Invitae Corp., Chief Scientific Officer at Arrogene, Inc., and EVP-Quality, Regulatory & Business Strategy at ArcherDX LLC.
She holds a graduate degree from The Trustees of Columbia University in The City of New York, an undergraduate degree from Indiana University, and a doctorate degree from Indiana University-Purdue University.
Postes actifs de Sandra Close
| Sociétés | Poste | Début |
|---|---|---|
Dante Labs, Inc.
 Dante Labs, Inc. Medical/Nursing ServicesHealth Services Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY. | Directeur/Membre du Conseil | 31/08/2021 |
Dante Labs International LLC
 Dante Labs International LLC Miscellaneous Commercial ServicesCommercial Services Dante Labs International LLC engages in provision of genomic tests. The company was founded on May 3, 2017 and is headquartered in New York, NY. | Directeur/Membre du Conseil | 31/08/2021 |
Foresight Diagnostics, Inc.
 Foresight Diagnostics, Inc. Medical/Nursing ServicesHealth Services Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation. | Directeur des opérations | 04/04/2022 |
Anciens postes connus de Sandra Close
| Sociétés | Poste | Fin |
|---|---|---|
Arrogene, Inc.
 Arrogene, Inc. Pharmaceuticals: MajorHealth Technology Arrogene, Inc. commercializes a cancer treatment technology and a proprietary molecular delivery platform. Its technology delivers peptide, protein and oligonucleotide therapeutics across the blood-brain barrier to cancer cells to prevent tumor growth or for imaging. The company was founded by Julia Ljubimova, Alexander Ljubimova, Keith Black and Eggehard Holler in 2006 and is headquartered in Los Angeles, CA. | Directeur Technique/Scientifique/R&D | - |
| INVITAE CORPORATION | Corporate Officer/Principal | - |
ArcherDX LLC
 ArcherDX LLC Packaged SoftwareTechnology Services ArcherDX LLC is a genomic analysis company, which develops software solutions for investigating cancer treatment. Its products include VariantPlex, FusionPlex, LiquidPlex, reveal ctDNA, Immunoverse, custom assays, and archer analysis. The company was founded by Jason W. Myers, A. John Iafrate, and Long Phi Le on January 1, 2013 and is headquartered in Boulder, CO. | Conseiller Juridique Général | - |
Formation de Sandra Close
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Indiana University | Undergraduate Degree |
| Indiana University-Purdue University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INVITAE CORPORATION | Health Services |
| Entreprise privées | 5 |
|---|---|
Arrogene, Inc.
Arrogene, Inc. Pharmaceuticals: MajorHealth Technology Arrogene, Inc. commercializes a cancer treatment technology and a proprietary molecular delivery platform. Its technology delivers peptide, protein and oligonucleotide therapeutics across the blood-brain barrier to cancer cells to prevent tumor growth or for imaging. The company was founded by Julia Ljubimova, Alexander Ljubimova, Keith Black and Eggehard Holler in 2006 and is headquartered in Los Angeles, CA. | Health Technology |
ArcherDX LLC
ArcherDX LLC Packaged SoftwareTechnology Services ArcherDX LLC is a genomic analysis company, which develops software solutions for investigating cancer treatment. Its products include VariantPlex, FusionPlex, LiquidPlex, reveal ctDNA, Immunoverse, custom assays, and archer analysis. The company was founded by Jason W. Myers, A. John Iafrate, and Long Phi Le on January 1, 2013 and is headquartered in Boulder, CO. | Technology Services |
Dante Labs, Inc.
Dante Labs, Inc. Medical/Nursing ServicesHealth Services Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY. | Health Services |
Dante Labs International LLC
Dante Labs International LLC Miscellaneous Commercial ServicesCommercial Services Dante Labs International LLC engages in provision of genomic tests. The company was founded on May 3, 2017 and is headquartered in New York, NY. | Commercial Services |
Foresight Diagnostics, Inc.
Foresight Diagnostics, Inc. Medical/Nursing ServicesHealth Services Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation. | Health Services |